# Alkaloid marked 8% growth in consolidated sales, 9% growth in consolidated net profit, sales in Great Britain in amount of MKD 172.6 million and 92 new employments in the period January - September 2017

> Alkaloid AD Skopje achieved positive financial results in the period January-September 2017 - shows the unaudited standalone and unaudited consolidated…

Source: https://alkaloid.com.mk/alkaloid-marked-growth-in-consolidated-sales-9-growth-in-consolidated-net-profit-sales-in-great-britain-in-amount-of-mkd-172million-and-92-new-employments-in-the-period-january-september-2017

Nov 2, 2017

Alkaloid AD Skopje achieved positive financial results in the period January-September 2017 - shows the unaudited standalone and unaudited consolidated Income Statement.

According to the unaudited standalone Income Statement, in the period January- September the sales reached the amount of MKD 5,143,210,986 - 7% up on the same period last year. Earnings before interest, taxes, depreciation and amortization (EBITDA), which amount to MKD 978,094,733 marked an increase of roughly 9%, whereas the net profit amounting to MKD 565,185,770 rose by 8%.

In the period January – September the total consolidated sales reached MKD 6,646,641,001 – an increase of 8% compared to the same period last year. Consolidated sales in the domestic market increased by 6%, while the total consolidated export of the company increased by 9%. Out of the total consolidated sales, 39% were realized in the domestic market, while the foreign markets account for 61%. The breakdown by region shows that the countries of South-East Europe account for 32% of the sales, Russia and CIS – 7%, 21% of the sales were realized in the countries from Western Europe (EU and EFTA), while the other markets account for 1% of the total consolidated sales. Noticeable rise was seen in Great Britain reaching sales of MKD 172,632,553 - increased by 15 times and Hungary with sales of MKD 23,977,965 – increased by 10 times compared to the same period last year. Growth in sales was also marked in the following export markets: Croatia – 9%, Romania – 69%, Slovenia - 13%, Russia – 5%, Ukraine - 36%, Montenegro – 10% etc.

The breakdown of total consolidated sales by group of products shows that the best sellers are the products from the segment Pharmaceuticals – 84%, with OTC products accounting for 21%, cardiovascular products - 17%, antibiotics - 13%, neurological products – 13% etc. The Chemistry Cosmetics Botanicals segment accounts for 16% of the total consolidated sales, or more precisely Chemistry – 3%, Cosmetics – 10% and Botanicals – 3%.

Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA), which reached MKD 1,018,511,003 saw an increase of 11%, whereas the net consolidated profit amounting to MKD 553,940,330 went up by 9%.

The total investments in non-current assets for the period January – September 2017 amounted to MKD 518,373,970.

In the period January – September 2017 Alkaloid recruited 92 new employees in the Republic of Macedonia.

Oct 29, 2026[ALKALOID – Operating Results for the January – September 2026 period](https://alkaloid.com.mk/alkaloid-operating-results-for-the-january-september-2026-period)

* * *

Oct 28, 2026[ALKALOID BECOMES THE FIRST COMPANY IN MACEDONIA TO RECEIVE THE PRESTIGIOUS TOP EMPLOYER 2026 CERTIFICATION](https://alkaloid.com.mk/alkaloid-top-employer-2026)

* * *

Oct 8, 2026[ALKALOID MARKS ITS 23RD PARTICIPATION IN CPHI, THE WORLD’S LEADING PHARMACEUTICAL EVENT](https://alkaloid.com.mk/alkaloid-marks-its-23-rd-participation-in-cphi-the-world-s-leading-pharmaceutical-event)

* * *

Sep 22, 2026[MUKAETOV AT THE 25TH MACEDONIAN STOCK EXCHANGE CONFERENCE: SMALL MARKET, BIG OPPORTUNITY](https://alkaloid.com.mk/mukaetov-at-the-25th-macedonian-stock-exchange-conference)

* * *

Sep 21, 2026[FROM ATOP A FACTORY CHIMNEY TO AN ART INSTALLATION: THE STORY OF ALKALOID’S HISTORIC SIGN](https://alkaloid.com.mk/from-atop-a-factory-chimney-to-an-art-installation-the-story-of-alkaloid-s-historic-sign)

* * *